EBS 8.10 ▼ -1.58% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Emergent BioSolutions Inc...

    NYSE: EBS · Real-Time Price · USD
    8.10
    -0.13 (-1.58%)
    At close: Sep 12, 2025, 10:12 AM
    -1.58%
    Bid 8.09
    Market Cap 431.88M
    Revenue (ttm) 846.2M
    Net Income (ttm) 139.5M
    EPS (ttm) 2.62
    PE Ratio (ttm) 3.09
    Forward PE 7.81
    Analyst Buy
    Ask 8.12
    Volume 87,762
    Avg. Volume (20D) 1,300,606
    Open 8.21
    Previous Close 8.23
    Day's Range 8.06 - 8.21
    52-Week Range 4.02 - 12.73
    Beta 2.04

    About EBS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol EBS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for EBS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Emergent BioSolutions Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 days ago
    +9.26%
    Emergent BioSolutions shares are trading higher af... Unlock content with Pro Subscription
    1 month ago
    +36.65%
    Emergent BioSolutions shares are trading higher after the company reported better-than-expected Q2 financial results.
    news image

    3 weeks ago · marketbeat.com

    Big Rallies Brewing? 3 Analyst Favorites to Watch Closely

    Companies can receive a big boost on impressive results or promising news, and then it is a matter of maintaining momentum to ensure those gains aren't given back shortly after.

    news image

    1 month ago · seekingalpha.com

    Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally

    Emergent BioSolutions delivered a strong Q2 2025, beating its own guidance and showing major improvements in margins. EBS has a sound turnaround strategy that is showing signs of success. The company ...

    news image

    1 month ago · seekingalpha.com

    Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript

    Emergent BioSolutions Inc. (NYSE:EBS ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Joseph C. Papa - CEO, President & Director Richard S.

    news image

    2 months ago · seekingalpha.com

    Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful

    Emergent stock is down >40% since my last update. I had given the stock a "Buy" rating but noted that 2025 may be a difficult year. Emergent's MCM business has performed well, but Narcan sales fell dr...

    Add to Watchlist